Ahmedabad, Gujarat, Jan 24, Torrent Pharma announces Q3 FY25 results, Net Profit after tax at Rs. 503 crores.
According to a press release issued by company here today Revenue & profitability: Revenue at Rs. 2,809 crores grew by 3%.
Gross Margin: 76.0%, Op. EBITDA margin at 32.5%.
Op. EBITDA at Rs.914 crores, up by 5%.
Net Profit after tax at Rs. 503 crores, up by 14%
No insulin CMO sales in the quarter. Dispatches restarted from January 2025.
During the quarter, BRL depreciated by 17% YoY.
Underlying revenue growth adjusted for above transient impact is 7% and Operating EBITDA growth is 12%.
Before exceptional items
: Exceptional items relate to net gain from the sale of a liquid facility in the US which was impaired during the earlier years.
Adjusted for Exceptional items, PAT growth for Q3 FY25 is 35%